Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
- Conditions
- Migraine With or Without Aura
- Interventions
- Registration Number
- NCT02605174
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
- Detailed Description
Participants will be asked to treat a migraine attack with study drug on an outpatient basis. Participants will be provided with a dosing card containing a dose for initial treatment and a second dose to be used for rescue or recurrence of migraine. Each participant's study participation will consist of screening (Visit 1) with a telephone contact within 7 days to confirm eligibility, a Treatment Period of up to 8 weeks, and End-of-Study (EoS) (Visit 2) within one week (7 days) of treating a single migraine attack. The total time on study is approximately up to 11 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3005
- Able and willing to give written informed consent and authorize HIPAA.
- Participants with migraine with or without aura fulfilling the International Headache Society (IHS) diagnostic criteria 1.1 and 1.2.1 (International Headache Classification (ICHD) 2004).
- History of disabling migraine for at least 1 year.
- Migraine Disability Association (MIDAS) score ≥11.
- Migraine onset before the age of 50 years.
- History of 3 - 8 migraine attacks per month (< 15 headache days per month).
- Male or female, aged 18 years or above.
- Females of child-bearing potential must be using or willing to use a highly effective form of contraception (e.g. combined oral contraceptive, intrauterine device (IUD), abstinence or vasectomized partner).
- Able and willing to complete an electronic diary to record details of the migraine attack treated with study drug.
- Any medical condition or clinical laboratory test which in the judgment of the Investigator makes the participant unsuitable for the study.
- Pregnant or breast-feeding women.
- Women of child-bearing potential not using or not willing to use highly effective contraception.
- Known hypersensitivity to lasmiditan or to any excipient of lasmiditan oral tablets, or any sensitivity to lasmiditan.
- History or evidence of hemorrhagic stroke, epilepsy or any other condition placing the participant at increased risk of seizures.
- History of recurrent dizziness and/or vertigo including benign paroxysmal positional vertigo (BPPV), Meniere's disease, vestibular migraine, and other vestibular disorders.
- History of diabetes mellitus with complications (diabetic retinopathy, nephropathy or neuropathy).
- History within the previous three years or current evidence of abuse of any drug, prescription or illicit, or alcohol.
- History of orthostatic hypotension with syncope.
- Significant renal or hepatic impairment.
- Participant is at imminent risk of suicide (positive response to question 4 or 5) on the Columbia-Suicide Severity Rating Scale (C-SSRS) or had a suicide attempt within six months prior to screening.
- Previous participation in this clinical trial.
- Participation in any clinical trial of an experimental drug or device in the previous 30 days.
- Known Hepatitis B or C or HIV infection.
- History, within past 12 months, of chronic migraine or other forms of primary or secondary chronic headache disorder (e.g. hemicranias continua, medication overuse headache) where headache frequency is ≥15 headache days per month.
- Use of more than 3 doses per month of either opiates or barbiturates.
- Initiation of or a change in concomitant medication to reduce the frequency of migraine episodes within three (3) months prior to Screening/Visit 1.
- Participants who are employees of the sponsor.
- Relatives of, or staff directly reporting to, the Investigator.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Lasmiditan 50 milligram (mg) Lasmiditan 50 mg Oral tablet. Lasmiditan 50 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours. Lasmiditan 200 mg Lasmiditan 200 mg Oral tablet. Lasmiditan 200 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours. Placebo Placebo Oral tablet. Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours. Lasmiditan 100 mg Lasmiditan 100 mg Oral tablet. Lasmiditan 100 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
- Primary Outcome Measures
Name Time Method Percentage of Participants Headache Pain Free at 2 Hours Post Dose 2 hours post dose The percentage of participants defined as mild, moderate, or severe headache pain becoming none.
Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free 2 hours post dose The percentage of participants defined as the associated symptom present and identified as MBS (nausea, photophobia, or phonophobia) prior to dosing being absent.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (92)
Alabama Clinical Therapeutics, LLC
🇺🇸Birmingham, Alabama, United States
Medical Affiliated Research Center, Inc. - ARC
🇺🇸Huntsville, Alabama, United States
21st Century Neurology
🇺🇸Phoenix, Arizona, United States
Anaheim Clinical Trials
🇺🇸Anaheim, California, United States
The Research Center of Southern California
🇺🇸Carlsbad, California, United States
eStudySite
🇺🇸Chula Vista, California, United States
Pharmacology Research Institute
🇺🇸Los Alamitos, California, United States
Pharmacology Research Institute, Newport Beach
🇺🇸Newport Beach, California, United States
Pacific Research Partners
🇺🇸Oakland, California, United States
Desert Valley Research
🇺🇸Rancho Mirage, California, United States
Scroll for more (82 remaining)Alabama Clinical Therapeutics, LLC🇺🇸Birmingham, Alabama, United States